[1]陈海燕,翟长云,王伟奇,等.升板方联合重组人白介素-11治疗化疗后血小板减少症的效果研究[J].医学信息,2022,35(03):172-174.[doi:10.3969/j.issn.1006-1959.2022.03.046]
　CHEN Hai-yan,ZHAI Chang-yun,WANG Wei-qi,et al.Study on the Effect of Shengbanfang Combined with Recombinant Human Interleukin-11in the Treatment of Thrombocytopenia After Chemotherapy[J].Medical Information,2022,35(03):172-174.[doi:10.3969/j.issn.1006-1959.2022.03.046]
点击复制

升板方联合重组人白介素-11治疗化疗后血小板减少症的效果研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年03期
页码:
172-174
栏目:
中医中药
出版日期:
2022-02-01

文章信息/Info

Title:
Study on the Effect of Shengbanfang Combined with Recombinant Human Interleukin-11in the Treatment of Thrombocytopenia After Chemotherapy
文章编号:
1006-1959（2022）03-0172-03
作者:
陈海燕; 翟长云; 王伟奇; 朱蓉蓉; 沈 洋; 王晋秋
盐城市大丰人民医院肿瘤科，江苏 盐城 224100
Author(s):
CHEN Hai-yan; ZHAI Chang-yun; WANG Wei-qi; ZHU Rong-rong; SHEN Yang; WANG Jin-qiu
Department of Oncology,Dafeng People’s Hospital,Yancheng 224100,Jiangsu,China
关键词:
化疗; 血小板减少症; 升板方; 重组人白介素-11; 凝血功能; 血小板计数
Keywords:
Chemotherapy; Thrombocytopenia; Shengbanfang; Recombinant human interleukin-11; Coagulation function; Platelet count
分类号:
R73；R973
DOI:
10.3969/j.issn.1006-1959.2022.03.046
文献标志码:
A
摘要:
目的 探讨对化疗后血小板减少症患者联合应用升板方与重组人白介素-11治疗的效果。方法 选择2019年3月-2021年2月本院接受化疗后出现血小板减少症的患者56例，按照随机数字表法分为联合组和对照组，各28例。对照组给予重组人白介素-11治疗，联合组在对照组的基础上加用升板方治疗，比较两组血小板计数（PLT）、凝血功能改善情况、治疗效果及不良反应发生率。结果 治疗7 d、14 d后，两组SPC均高于治疗前，联合组高于对照组（P＜0.05）；联合组的SPC≤30×109/L、SPC≥75×109/L持续时间均较对照组短（P＜0.05）；治疗14 d后，两组FIB水平较治疗前上升，PT、APTT、TT较治疗前下降；且联合组FIB水平高于对照组，PT、APTT、TT水平低于对照组（P＜0.05）；联合组的治疗有效率为89.29%，略高于对照组的71.43%，但差异无统计学意义（P＞0.05）；联合组用药后不良反应发生率为7.14%，较对照组的17.86%低，但差异无统计学意义（P＞0.05）。结论 联合应用升板方与重组人白介素-11治疗化疗后血小板减少症效果确切，可控制病情进展，促进血小板计数恢复正常，还可调节机体凝血功能，且用药后不良反应发生率低，治疗安全性高。
Abstract:
Objective To explore the effect of combining Shengbanfang and recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy.Methods A total of 56 patients with thrombocytopenia after chemotherapy in our hospital from March 2019 to February 2021 were randomly divided into combined group and control group, with 28 cases in each group. The control group was treated with recombinant human interleukin-11, and the combined group was treated with Shengban decoction on the basis of the control group. The platelet count (PLT), improvement of coagulation function, therapeutic effect and incidence of adverse reactions were compared between the two groups.Results After 7 d and 14 d of treatment, the SPC of the two groups were higher than those before treatment, and the combined group was higher than the control group(P<0.05).The duration of SPC≤30×109/L and SPC≥75×109/L in the combined group were shorter than those in the control group(P<0.05). After 14 days of treatment, the level of FIB in the two groups were higher than those before treatment, the levels of PT, APTT and TT were lower than those before treatment, the level of FIB in the combined group was higher than that in the control group, and the levels of PT, APTT and TT were lower than those of the control group(P<0.05). The effective rate of the combined group was 89.29%, which was slightly higher than 71.43% of the control group, but the difference was not statistically significant (P>0.05). The incidence of adverse reactions in the combined group was 7.14%, which was lower than 17.86% in the control group, but the difference was not statistically significant (P>0.05).Conclusion The combined application of Shengbanfang and recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy is effective, which can control the progression of the disease, promote the recovery of platelet count, and regulate the coagulation function of the body. The incidence of adverse reactions after treatment is low, and the treatment safety is high.

参考文献/References:

[1]中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J].中华血液学杂志,2020,41(8):617-623.[2]吴芙蓉,杨昭毅,李民,等.42例药源性血小板减少症的帕累托分析[J].中国医院用药评价与分析,2021,21(2):240-243.[3]吕晓伟,毕作木,周其锋.重组人血小板生成素对促进急性髓系白血病化疗后血小板减少恢复的作用[J].中国临床研究,2019(4):4.[4]Li ZY,Zhang Z,Cao XZ,et al.Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis[J].J Int Med Res,2020,48(10):300060520964340.[5]袁志军,刘爱林.益气升化汤与泼尼松联合治疗特发性血小板减少性紫癜疗效及对血清生化指标的影响[J].现代中西医结合杂志,2018,27(21):2350-2353.[6]中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J].中国医学前沿杂志(电子版),2020,12(1):51-58.[7]董晓敏,毛柳珺,陈铂,等.升红颗粒对小鼠化疗后血小板减少症的疗效研究[J].华夏医学,2017,30(2):6-8.[8]Meintker L,Krause SW.Reticulated platelets-Clinical application and future perspectives[J].Journal of Laboratory Medicine,2020,44(5):241-253.[9]季菲,贺晓芳,胡晓梅,等.滋阴和阳方治疗激素依赖原发免疫性血小板减少症临床研究[J].国际中医中药杂志,2020,42(11):1058-1063.[10]杨阳,胡美薇,傅丽娟,等.加味黄芪建中汤通过调节miR-516a-5P治疗血小板减少症[J].中国病理生理杂志,2021,37(4):718-724.[11]董方杰,马宁,常思远,等.重组人血小板生成素在脓毒症伴血小板减少症患者中的作用[J].中华危重病急救医学,2020,32(12):1445-1449.[12]林琳,杨冉,姚浩,等.成人原发免疫性血小板减少症中医体质类型临床研究[J].中华中医药杂志,2021,36(1):520-522.[13]陈静.重组人血小板生成素对白血病化疗后血小板减少症的疗效观察[J].吉林医学,2020,41(4):883-884.[14]陈红涛.益气填精、温补脾肾治疗化疗后血小板减少症的疗效观察[J].光明中医,2010,25(12):2211-2213.[15]张蓓,胡丕丽,丘惠娟,等.升板方治疗肿瘤化疗后血小板减少症的临床观察[J].广东医学,2001(10):972.[16]Ouyang G,Pan G,Xu H,et al.Sorafenib Plus HePatic Arterial Infusion ChemotheraPy in Advanced HePatocellular Carcinoma[J].Journal of Clinical Gastroenterology,2020,54(8):675-681.[17]熊兴江.基于现代病理生理及CCU急危重症病例的炙甘草汤方证溯源及其复律、转窦、止血、升血小板、补虚临床运用[J].中国中药杂志,2019,44(18):3842-3860.[18]沈君华.升板方联合重组人白介素-2治疗化疗后血小板减少疗效观察[J].实用中医药杂志,2019,35(10):1241-1242.[19]王蕾,黄双佳,符一岚,等.重组人白介素-11致1例毛细血管渗漏综合征的分析[J].药学与临床研究,2021,29(2):143-145.

相似文献/References:

[1]宁尚波,杨东红,付 爽.选择性动脉灌注化疗在口腔癌治疗中的进展[J].医学信息,2018,31(03):28.[doi:10.3969/j.issn.1006-1959.2018.03.009]
　NING Shang-bo,YANG Dong-hong,FU Shuang.Progress of Selective Arterial infusion Chemotherapy in the Treatment of Oral Cancer[J].Medical Information,2018,31(03):28.[doi:10.3969/j.issn.1006-1959.2018.03.009]
[2]李杰萍,姜翠红,管树荣,等.化疗患者PICC置管前后心理体验的质性研究[J].医学信息,2018,31(05):164.[doi:10.3969/j.issn.1006-1959.2018.05.060]
　I Jie-ping,JIANG Cui-hong,GUAN Shu-rong,et al.Qualitative Study of Psychological Experience before and after PICC Catheterization in Patients undergoing Chemotherapy[J].Medical Information,2018,31(03):164.[doi:10.3969/j.issn.1006-1959.2018.05.060]
[3]庞小坤,韩 梅,江心灿,等.当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析[J].医学信息,2019,32(02):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
　Pang Xiao-kun,Han Mei,Jiang Xin-can,et al.Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy[J].Medical Information,2019,32(03):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
[4]胡雪瑞,戢艳琼.1例PCI术后盐酸替罗非班诱导的极重度血小板减少的护理[J].医学信息,2018,31(14):183.[doi:10.3969/j.issn.1006-1959.2018.14.058]
　HU Xue-rui,JI Yan-qiong.Nursing Care of a Case of Extremely Severe Thrombocytopenia Induced by Tirofiban Hydrochloride after PCI[J].Medical Information,2018,31(03):183.[doi:10.3969/j.issn.1006-1959.2018.14.058]
[5]张祖雪,吴治敏,王 艳.1例滋养细胞疾病患者化疗后并发严重口腔溃疡护理[J].医学信息,2019,32(01):183.[doi:10.3969/j.issn.1006-1959.2019.01.060]
　ZHANG Zu-xue,WU Zhi-min,WANG Yan.1 Case of Trophoblastic Disease with Severe Oral Ulcer Care after Chemotherapy[J].Medical Information,2019,32(03):183.[doi:10.3969/j.issn.1006-1959.2019.01.060]
[6]万 卉.中西医结合护理改善乳腺癌化疗患者生活质量的临床观察[J].医学信息,2019,32(11):185.[doi:10.3969/j.issn.1006-1959.2019.11.058]
　WAN Hui.Clinical Observation on Integrating Traditional Chinese Medicine with Western Medicine to Improve the Quality of Life of Patients with Breast Cancer Chemotherapy[J].Medical Information,2019,32(03):185.[doi:10.3969/j.issn.1006-1959.2019.11.058]
[7]王秀秀.认知行为疗法联合睡眠护理模式对乳腺癌术后化疗患者的影响研究[J].医学信息,2022,35(13):183.[doi:10.3969/j.issn.1006-1959.2022.13.046]
　WANG Xiu-xiu.Effect of Cognitive Behavioral Therapy Combined with Sleep Nursing Mode on Postoperative Chemotherapy in Patients with Breast Cancer[J].Medical Information,2022,35(03):183.[doi:10.3969/j.issn.1006-1959.2022.13.046]
[8]龚建忠,韦 燕,潘琦津,等.锌剂防治鼻咽癌同步放化疗患者放射性口咽炎的效果分析[J].医学信息,2019,32(17):63.[doi:10.3969/j.issn.1006-1959.2019.17.020]
　GONG Jian-zhong,WEI Yan,PAN Qi-jin,et al.Effect of Zinc on Prevention and Treatment of Radiation Oropharyngeal Mucositis in Patients with Nasopharyngeal Carcinoma Treated with Concurrent Chemoradiotherapy[J].Medical Information,2019,32(03):63.[doi:10.3969/j.issn.1006-1959.2019.17.020]
[9]刘 筠.异环磷酰胺与依托泊苷联合治疗 复发卵巢癌的临床效果[J].医学信息,2019,32(13):143.[doi:10.3969/j.issn.1006-1959.2019.13.044]
　LIU Jun.Clinical Effect of Combination of Ifosfamide and Etoposide inTreatment of Recurrent Ovarian Cancer[J].Medical Information,2019,32(03):143.[doi:10.3969/j.issn.1006-1959.2019.13.044]
[10]陈 成,徐 成,姚 衡,等.CINV的中西医临床防治研究[J].医学信息,2019,32(21):49.[doi:10.3969/j.issn.1006-1959.2019.21.017]
　CHEN Cheng,XU Cheng,YAO Heng,et al.CINV's Clinical Research on Prevention and Treatment of Traditional Chinese and Western Medicine[J].Medical Information,2019,32(03):49.[doi:10.3969/j.issn.1006-1959.2019.21.017]
[11]徐广春.个性化护理在改善淋巴瘤化疗后血小板减少症中的作用及安全性[J].医学信息,2023,36(11):168.[doi:10.3969/j.issn.1006-1959.2023.11.036]
　XU Guang-chun.The Role and Safety of Personalized Nursing in Improving Thrombocytopenia After Lymphoma Chemotherapy[J].Medical Information,2023,36(03):168.[doi:10.3969/j.issn.1006-1959.2023.11.036]

更新日期/Last Update: 1900-01-01